Клиничка дијагностичка вредност нових серумских маркера липазе Ф, гастрина 2 и Кс-типа колагена α1 ланца код карцинома желуца

Serum markers lipase F, gastrokine 2 and the collagen X-type α1 chain in gastric cancer

  • Fashe Wang Болница Нинбо Мингчжоу, провинција Чжешанг
  • Bai Li Прва придружена болница Медицинског универзитета Фујиан
  • Shangyin Li Прва придружена болница Медицинског универзитета Фујиан
  • Yan Tang Fujian Medical University First Affiliated Hospital
  • Tao Tan Трећа народна болница провинције Хубеи Универзитет Јиангхан
DOI: https://doi.org/10.5937/jomb0-59476

Sažetak


Objective: To explore the application value of three novel serum markers, collagen X-type α1 chain (COL10A1), gastrokine 2 (GKN2), and lipase F (LIPF), in the diagnosis of gastric cancer.

Methods: Differential markers of gastric cancer were mined from public databases (TCGA, GTEx). From November 2022 to October 2024, 108 healthy people and patients with stomach cancer who had gastroscopies and pathological examinations at our hospital were chosen to serve as research subjects. Of these, 60 patients had stomach cancer (28 in the early gastric cancer group and 32 in the advanced gastric cancer group), while 48 patients were in the healthy group. Receiver operating characteristic (ROC) curves were created in order to examine the relationship between the detection of gastric cancer and the serum levels of markers. Additionally, the application value of both the detection of new markers and the detection of conventional markers (PGI, PGII) in the diagnosis of gastric cancer was examined.

Results: Three differential markers of gastric cancer (COL10A1, GKN2 and LIPF) were mined from a public database. By detecting the levels of three markers in clinical blood samples, AUC of the combined detection of the three markers (COL10A1+GKN2+LIPF, 3MP) in differentiating group (3MP vs PGR: 0.842 vs 0.841) and the early gastric cancer group (0.877 vs 0.843) was greater than that of PGR (PGI/PGII). The combined conventional markers (PGI, PGII) and the combined detection of five markers (3MP+PGI+PGII, 5MP) had AUCs of 0.963 and 0.953, respectively.

Conclusion: COL10A1, GKN2 and LIPF are very promising serum markers for the diagnosis of gastric cancer. The joint detection of the serum levels of these three novel markers and PGI and PGII has important value for the early detection of gastric cancer.

Reference

1.Zhang M, Jin M, Gao Z, Yu W, Zhang W. High COL10A1 expression potentially contributes to poor outcomes in gastric cancer with the help of LEF1 and Wnt2. J Clin Lab Anal. 2022 Sep;36(9):e24612.
2.Yi Q, Zhu G, Zhu W, Wang J, Ouyang X, Yang K, Zhong J. Oncogenic mechanisms of COL10A1 in cancer and clinical challenges (Review). Oncol Rep. 2024 Dec;52(6):162.
3.Aktas SH, Taskin-Tok T, Al-Khafaji K, Akın-Balı DF. A detailed understanding of the COL10A1 and SOX9 genes interaction based on potentially damaging mutations in gastric cancer using computational techniques. J Biomol Struct Dyn. 2022;40(22):11533-11544.
4.Shen N, Zhu S, Zhang Z, Yong X. High Expression of COL10A1 Is an Independent Predictive Poor Prognostic Biomarker and Associated with Immune Infiltration in Advanced Gastric Cancer Microenvironment. J Oncol. 2022 Oct 13;2022:1463316.
5.Liu Z, Sun L, Zhu W, Zhu J, Wu C, Peng X, Tian H, Huang C, Zhu Z. Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer. Biol Direct. 2024 Aug 15;19(1):65.
6.Sun C, Chen Y, Kim NH, Lowe S, Ma S, Zhou Z, Bentley R, Chen YS, Tuason MW, Gu W, Bhan C, Tuason JPW, Thapa P, Cheng C, Zhou Q, Zhu Y. Identification and Verification of Potential Biomarkers in Gastric Cancer By Integrated Bioinformatic Analysis. Front Genet. 2022 Jul 15;13:911740.
7.Wang X, Bai Y, Zhang F, Li D, Chen K, Wu R, Tang Y, Wei X, Han P. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation. Front Immunol. 2023 Mar 17;14:955949.
8.Xie Z, Zhao W, He Y, Ke Y, Li Z, Zhang X. Mutational and transcriptional profile predicts the prognosis of stage IV gastric cancer - Prognostic factors for metastatic gastric cancer. Arab J Gastroenterol. 2024 Aug;25(3):275-283.
9.Moreira AM, Ferreira RM, Carneiro P, Figueiredo J, Osório H, Barbosa J, Preto J, Pinto-do-Ó P, Carneiro F, Seruca R. Proteomic Identification of a Gastric Tumor ECM Signature Associated With Cancer Progression. Front Mol Biosci. 2022 Mar 1;9:818552.
10.Wang T, Bao X, Yang F, Pan S, Xu K, Ren T. Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Onco Targets Ther. 2024 Nov 6;17:949-959.
11.Shen W, Zhou H, Li L, Liu W, Lou Q, Tong CY, Gao J, Gao J, Shao P. Promising protein biomarkers for early gastric cancer: clinical performance of combined detection. Clin Chem Lab Med. 2025 May 1.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852.
13.Guo S, Wang E, Wang B, Xue Y, Kuang Y, Liu H. Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer : Prognosis Prediction for Resectable GC. Ann Surg Oncol. 2024 Mar;31(3):2078-2089.
14.Li Y, Luo Y, Tian Q, Lai Y, Xu L, Yun H, Liang Y, Liao D, Gu R, Liu L, Yuan M, Li Y, Li Y, Lu M, Yong X, Zhang H. Integrated Bioinformatics Analysis for Identifying the Significant Genes as Poor Prognostic Markers in Gastric Adenocarcinoma. J Oncol. 2022 Jun 11;2022:9080460.
15.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248.
16.Hou W, Zhao Y, Zhu H. Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects. Int J Mol Sci. 2023 Oct 18;24(20):15321.
17.Christodoulidis G, Koumarelas KE, Kouliou MN. Revolutionizing gastric cancer treatment: The potential of immunotherapy. World J Gastroenterol. 2024 Jan 28;30(4):286-289.
18.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861.
19.Duan Y, Xu Y, Dou Y, Xu D. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025 Jan 23;18(1):10.
20.Kono K, Nakajima S, Mimura K. Biomarker-oriented chemo-immunotherapy for advanced gastric cancer. Int J Clin Oncol. 2024 Jul;29(7):865-872.
21.Jiang X, Zhu Z, Ding L, Du W, Pei D. ALKBH4 impedes 5-FU Sensitivity through suppressing GSDME induced pyroptosis in gastric cancer. Cell Death Dis. 2024 Jun 20;15(6):435.
22.Yang YN, Wang LS, Dang YQ, Ji G. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors. World J Gastroenterol. 2024 Aug 28;30(32):3726-3729.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603.
24.Li J, Wu Z, Lin R. Impact of Helicobacter pylori on immunotherapy in gastric cancer. J Immunother Cancer. 2024 Oct 22;12(10):e010354.
25.Hosseini SA, Haddadi MH, Fathizadeh H, Nemati F, Aznaveh HM, Taraj F, Aghabozorgizadeh A, Gandomkar G, Bazazzadeh E. Long noncoding RNAs and gastric cancer: An update of potential biomarkers and therapeutic applications. Biomed Pharmacother. 2023 Jul;163:114407.
26.Deng J, Zhang W, Xu M, Zhou J. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy. Abdom Radiol (NY). 2023 Dec;48(12):3661-3676.
27.Moreno-Sánchez M, Cubiella J, Fernández Esparrach G, Marin-Gabriel JC. Image-enhanced endoscopy in the diagnosis of gastric premalignant conditions and gastric cancer. Gastroenterol Hepatol. 2023 May;46(5):397-409. English, Spanish.
28.Díaz Del Arco C, Fernández Aceñero MJ, Ortega Medina L. Liquid biopsy for gastric cancer: Techniques, applications, and future directions. World J Gastroenterol. 2024 Mar 28;30(12):1680-1705.
29.Ma Y, Jiang Z, Pan L, Zhou Y, Xia R, Liu Z, Yuan L. Current development of molecular classifications of gastric cancer based on omics (Review). Int J Oncol. 2024 Sep;65(3):89.
Objavljeno
2025/08/21
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2025 Fashe Wang, Bai Li, Shangyin Li, Yan Tang, Tao Tan

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.